CNS Pharmaceuticals Inc. (CNSP)
CNSP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CNSP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001729427 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-12 |
| Cash and burn | $20.0M cash; operating cash flow -$3.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,461,449 (2026-08-11); 574,580 a year earlier; 4,201,930 three years earlier. 3y figure adjusted for splits (1-for-30000 overall). | Cover page 2026-08-11 |
| Reverse splits, 3 years | 3; latest 1-for-12 on 2025-07-22 | Source 2025-07-22 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MaloneBailey, LLP, Houston, Texas, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $44K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$2.6M | -$3.5M | $20.0M | $300K | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$4.9M | -$4.6M | $3.0M | $232K | Needs four quarters | 10-Q 2026-08-12 |
| Q4 2025 2025-12-31 | Not filed | -$6.0M | -$3.1M | $7.2M | $628K | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$3.2M | -$2.2M | $9.9M | $31K | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.4M | -$5.3M | $12.1M | $122K | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$4.3M | -$3.2M | $13.0M | $211K | Needs four quarters | 10-Q 2026-08-12 |
| Q4 2024 2024-12-31 | Not filed | -$3.2M | -$5.5M | $6.5M | $326K | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$5.6M | -$6.8M | $7.0M | $31K | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 424B3 PROSPECTUS | 424B3 | 2026-05-26 |
| Latest annual report AMENDMENT #1 TO FORM 10-K | 10-K/A | 2026-04-30 |
| Latest quarterly / interim FORM 10-Q FOR SEP 2026 | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-10-02 |
| Latest proxy | DEFA14A | 2026-08-25 |
Source: SEC EDGAR submissions feed, 391 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -26.3% |
| 1 month | -46.0% |
| 3 months | -43.9% |
| Year to date | -45.0% |
| 1 year | -55.2% |
| From 52-week high | -63.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JAGX | Jaguar Health Inc. | $0.3864 | -7.74% | $5.2M |
| CVKD | Cadrenal Therapeutics Inc. | $1.40 | -7.28% | $5.0M |
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| ACXP | Acurx Pharmaceuticals Inc. | $0.9350 | -2.60% | $5.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier